Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

o study population pharmacokinetics in Benznidazole-treated adult patients with Chronic Chagas Disease to get information to optimize drug doses.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Barcelona Centre for International Health Research
• Treatments: Benzonidazole

Criteria

Inclusion Criteria:

• Adult patients with Chronic Chagas Disease diagnosed by 2 different and positive serological tests.

• Patients with Chronic Chagas Disease who are going to start treatment with Benznidazole.

• Any gender.

• All the participants must agree to participate in the study and must sign the informed consent.

Exclusion Criteria:

• Patients younger than 18.

• Patients with previous hypersensitivity to Benznidazole.

• Immunocompromised patients as AIDS, cancer, chemotherapy, longterm corticoids need, primary immunodeficiency, or any other.

• Hepatic dysfunction

• Renal dysfunction: serum creatinin higher than 3 mg/dl.

• Pregnancy or lactation.

• Low adhesion to treatment or check-up.

• Impossibility of follow-up.

• Severe adverse reaction to Benznidazole.

• Any other situation that could be risky for the patient.